These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22286586)

  • 1. Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.
    Hochhaus A; Reiter A; Ernst T; La Rosée P
    Onkologie; 2012; 35 Suppl 1():34-41. PubMed ID: 22286586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
    Krystal GW
    Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of signal transduction inhibition: basic science to novel therapies.
    Griffin J
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
    Nimmanapalli R; Bhalla K
    Oncogene; 2002 Dec; 21(56):8584-90. PubMed ID: 12476305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM; Talpaz M
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
    Tauchi T; Ohyashiki K
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.